References

1. Lapins J, Jarstrand C, Emtestam L. Coagulase-nega-tive staphylococci are the most common bacteria found in cultures from the deep portions of hi-dradenitis suppurativa lesions, as obtained by carbon dioxide laser surgery. Br J Dermatol 1999; Jan, 140(1):90-5

2. Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 1983; 22:325-328

3. Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hi-dradenitis suppurativa. J Am Acad Dermatol 1998; 39:971-974

4. Akhavan A, Bershad S. Topical acne drugs: review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol 2003; 4:473-492

5. Krautheim A, Gollnick H. Transdermal penetration of topical drugs used in the treatment of acne. Clin Pharmacokinet 2003; 42:1287-1304

6. Parry MF, Rha CK. Pseudomembranous colitis caused by topical clindamycin phosphate. Arch Dermatol 1986; 122:583-584

7. Milstone EB, McDonald AJ, Scholhamer CF Jr. Pseudomembranous colitis after topical application of clindamycin. Arch Dermatol 1981; 117:154-155

8. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, Shalita A, Thiboutot D. Management of acne. Topical retinoids. J Am Acad Dermatol 2003; 49 [Suppl 1]:S5-S11

9. Yu CC, Cook MG. Hidradenitis suppurativa: a disease of follicular epithelium rather than apocrine glands. Br J Dermatol 1990; 122:763-769

10. Attanoos R, Appleton MAC, Douglas-Jones AG. The pathogenesis of hidradenitis suppurativa: a closer look at apocrine and apoeccrine glands. Br J Dermatol 1995; 133:254-258

11. Boer J, Weltevreden EF. Hidradenitis suppurativa or acne inversa: a clinicopathological study of early lesions. Br J Dermatol 1996; 135:721-725

12. Boer J, Dijkstra AT, Baar TJM, Meer JB van der. Hidradenitis suppurativa (acne inversa): Lokale be-handeling met resorcine. Ned Tijdschr Derm Vene-reol 2001; 11:348-349

13. Boer J, Bos WH, Meer JB van der. Hidradenitis sup-purativa (acne inversa): behandeling met deroofing en resorcine [English abstract]. Ned Tijdschr Derm Venereol 2004; 14:274-278

14. Braun Falco O, Plewig G, Wolff HH, Burgdorf WHC. Diseases of the sebaceous Glands. In: Braun Falco O, Plewig G, Wolff HH, Burgdorf WHC (eds) Dermatology, 4th revised edn. Springer, Berlin Heidelberg New York, 1996; pp 1051-1082

15. Webster GF. Acne vulgaris. Br Med J 2002; 325:475479

16. Stienstra P. Hidradenitis suppurativa. In: Jansen LH (ed) Huid en geslachtsziekten. Scheltema en Holke-ma, Utrecht, 1975; pp 121-125

17. Polano MK. Topical therapeutics. Churchill Livingstone, Edinburgh, 1984

18. Groot de AC. Dermatological drugs, topical agents and cosmetics. In: Dukes MNG, Aronson JK (eds) Meyler's side effects of drugs, 14th edn. Elsevier, Amsterdam, 2000; p 473

19.Degreef H, Hulsebos HJ, Marien KJC, Schroeff JG van der. Behandelingsprincipes. In: Vloten WA, van, Degreef HJ, Stolz E, Vermeer BJ, Willemze R (eds) Dermatologie en Venereologie, 3rd edn. Elsevier, Amsterdam, 2000.

20. Mills OH, Kligman AM. Assay of comedolytic activity in acne patients. Acta Dermatovenereol 1982; 63:68-71

21. Mills OH, Kligman AM. Drugs that are ineffective in the treatment of acne vulgaris. Br J Dermatol 1983; 108:371-374

22. Wüthrich B, Zabrodsky S, Storck H. Perkutane Vergiftungen durch Resorcin, Salicylsäure und weisse Präcipitatsalbe. Pharmaceutica Acta Helvetiae 1970; 45:453-460

23. Häckh G, Schwarzmüller E. Codex dermatologischer Wirkstoffe. In: Niedner R, Ziegenmeyer J (eds) Dermatika. Wissenschaftliche Verlagsgesellschaft, Stuttgart, 1992; pp 447-448

24. Werth von der JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2000; 14:389-392

25. Cunliffe WJ. Looking back to the future - acne. Dermatology 2002; 204:167-172

26. Cassano N, Alessandrini G, Mastrolonardo M, Vena GA. Peeling agents: toxicological and allergo-logical aspects. J Eur Acad Dermatol Venereol 1999; 13:14-23

27. Bontemps H, Mallaret M, Besson G, Bochaton H, Carpentier F. Confusion after topical use of resor-cinol. Arch Dermatol 1995; 131:112

28. Cunningham AA. Resorcine poisoning. Arch Dis Child 1956; 31:173-176

29. Plas M van der, Bos WH. Chirurgische behandel-ing (epitheliale adnexcysten) door de dermatoloog [English abstract]. Ned Tijdschr Derm Venereol 1994; 4:101-103

30. Breathnach AS. Azelaic acid: potential as a general antitumoural agent. Med Hypotheses 1999; 52:221226

31. Brasch J, Christophers E. Azelaic acid has anti-mycotic properties in vitro. Dermatology 1993; 186:55-58

32. Detmar M, Mayer-da-Silva A, Stadler R, Orfanos CE. Effects of azelaic acid on proliferation and ultrastructure of mouse keratinocytes in vitro. J Invest Dermatol 1989; 93:70-74

33. Topert M, Rach P, Siegmund F. Pharmacology and toxicology of azelaic acid. Acta Dermatol Venereol Suppl (Stockh) 1989; 143:14-19

34. Passi S, Picardo M, Mingrone G, Breathnach AS, Nazzaro-Porro M. Azelaic acid - biochemistry and metabolism. Acta Dermatol Venereol Suppl (Stockh) 1989; 143:8-13

35. Galhaup I. Azelaic acid: mode of action at cellular and subcellular levels. Acta Dermatol Venereol Suppl (Stockh) 1989; 143:75-82

36. Bojar RA, Holland KT, Leeming JP, Cunliffe WJ. Azelaic acid: its uptake and mode of action in Staphylococcus epidermidis NCTC 11047. J Appl Bacteriol 1988; 64:497-504

37. Wilkinson JD. Fusidic acid in dermatology. Br J Dermatol 1998;139 [Suppl] 53:37-40

38. Levine RM, Rasmussen JE. Intralesional corticoste-roids in the treatment of nodulocystic acne. Arch Dermatol 1983; 119:480-481

39. Jansen T, Romiti R, Plewig G, Altmeyer P. Disfiguring draining sinus tracts in a female acne patient. Pediatr Dermatol 2000; 17:123-125

Chapter 22

Surgery

22

Jan Lapins, Lennart Emtestam

Acne Attack

Acne Attack

This Book Below Will Show You Exactly What You Need To Beat Your Acne!

Get My Free Ebook


Post a comment